

Spondyloarthritis Committee meeting

Date: 18th and 19th April 2016

Location: Dee 2, NICE Manchester

Minutes: Final

Committee members present:		
	Day 1	Day 2
Gary McVeigh (Chair) (GM)	Present for all items	Present for all items
David Chandler (DCh)	Present for all items	Present until near the end of item 7
Debbie Cook (DC)	Present for all items	Present until partway through item 6
Charlotte Davis (CD)	Present for all items	Present for all items
Nicola Goodson (NG)	Present for all items	Present for all items
Tina Hawkins (TH)	Present for all items	Apologies
Amanda Isdale (AI)	Present for all items	Present until near the end of item 7
Jon Packham (JP)	Present for all items	Present for all items
Carol McCrum (CM)	Present for all items	Present for all items
Tim Orchard (TO)	Present until partway through item 5	Apologies
Louise Warburton (LW)	Present for all items	Present until partway through item 6

In attendance:		
	Day 1	Day 2
Ciara Donnelly (CDO) Business Analyst	Apologies	Present until near the end of item 7
Rachel Houten (RH) Health Economist	Present for all items	Present for all items
Katherine McAllister (KM) Technical Analyst	Present from partway through item 3	Present for all items

SA GDG 13 minutes

Vonda Murray (VM) Project Manager	Present for all items	Present for all items
Sarah Palombella (SPA) Senior Medical Editor	Present for all items	Present for all items
Joshua Pink (JPK) Technical Advisor	Apologies	Present from partway through item 3
Gabriel Rogers (GR) - Technical Advisor (HE)	Apologies	Present for all items
Sue Spiers (SP) Associate Director	Apologies	Present for all items

Observers:	Day 1	Day 2
Helen Dickinson Guideline Coordinator	Present for all items	Not present

Apologies:	
Jemma Dean	Information Specialist
Alasdair Dennison	Co-opted expert
Sue Ellerby	Clinical Advisor
Amanda Isdale	Committee member
Caroline Keir	Commissioning Manager
Philip O'Connor	Co-opted expert
Shelly Patel	Medicines Advisor
Winston Rennie	Co-opted expert

1. Welcome, minutes of the last meeting, declarations of interest and objectives for the meeting

The Chair welcomed the committee members and attendees to the 1st day of the 13th guideline development group meeting. He introduced SPA and TO, to the committee.

Apologies were noted, as recorded above, and minutes of the last meeting were agreed as an accurate record.

All Committee members were asked to share any new conflicts of interest which have not previously been declared. No new conflicts were identified. The Chair reviewed historical declaration of interests it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The Chair provided a brief overview of the objectives for the day highlighting the

SA GDG 13 minutes

information that would be discussed.

2. Role of the editor

SPA talked about the various versions of the guideline that NICE publishes, and how the editor can support the committee in their work. An invitation was extended to committee members to attend an editorial meeting: 4.11.16, 13.30 – 4.00.

Committee members who would like to attend should email VM

3. Health Economics parameters

RH presented to the committee the parameters used for the spondyloarthritis health economic model

4. RQ4 What is the diagnostic utility of a risk assessment score for identifying spondyloarthritis?

KM provided a summary of the agreed analysis plan, presented the evidence found on diagnostic utility of a risk assessment scores for identifying spondyloarthritis.

5. Recap

- RQ1 What signs and symptoms should prompt a healthcare professional to think of spondyloarthritis?
- RQ2 What risk factors should increase suspicion of spondyloarthritis?
- RQ7 What is the diagnostic utility of a HLA B27 test for investigating suspected spondyloarthritis?
- Rq8 What is the diagnostic utility of an erythrocyte sedimentation rate test for investigating suspected spondyloarthritis?
- Rq9 What is the diagnostic utility of a C-reactive protein test for investigating suspected spondyloarthritis?

The recommendations made to date were reviewed and updated.

6. RQ10 What is the diagnostic utility of imaging (alone or in sequence) for investigating suspected spondyloarthritis?

KM reminded the committee of the agreed analysis plan and presented the evidence from the included studies. Based on the evidence presented and their own clinical experience and expertise the committee recommendation around the diagnostic utility of imaging for investigating suspected spondyloarthritis.

7. Summary and next steps

There were no additional matters arising. The Chair briefly summarised the discussions from the meeting before closing day 1.

Day 2

1. Welcome, minutes of the last meeting, declarations of interest and objectives for the meeting
<p>The Chair welcomed the Committee members to day 2 of the 13th guideline development group meeting. The Chair went through the revised agenda for day 2, giving a brief overview of what would be discussed.</p> <p>Apologies were noted, as recorded above.</p> <p>No new conflicts of interest were declared and it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.</p>
2. Resource impact process
<p>CDO explained the role of the team in the guideline process, and how they support the committee in developing the guideline.</p>
3. Lower back pain guideline
<p>GR provided a summary of the comments received from committee members on the lower back pain guideline in relation to the spondyloarthritis guideline.</p> <p>GR will prepare a stakeholder response on behalf of the committee and circulate for comment</p>
4. RQ10 What is the diagnostic utility of imaging (alone or in sequence) for investigating suspected spondyloarthritis?
<p>KM provided additional information to answer questions raised by the committee from day 1.</p>
5. RQ4 What is the diagnostic utility of a risk assessment score for identifying spondyloarthritis?
<p>KM presented additional evidence, which was considered by the committee and the recommendation was updated.</p>
6. RQ1 What signs and symptoms should prompt a healthcare professional to think of spondyloarthritis?
<p>RQ2 What risk factors should increase suspicion of spondyloarthritis?</p>
<p>Further discussion by the committee around the signs, symptoms and risk factors that may indicate spondyloarthritis</p>
7. Health economics model
<p>RH presented aspects of the model to the committee, which were discussed and</p>

SA GDG 13 minutes

agreed

8. Summary and next steps

The Chair thanked the committee for their work.

Next meeting

GDG14 Monday 20th and Tuesday 21st June 2016 – Manchester NICE Offices